JP4426110B2 - 自己抗体のためのアッセイ - Google Patents
自己抗体のためのアッセイ Download PDFInfo
- Publication number
- JP4426110B2 JP4426110B2 JP2000578660A JP2000578660A JP4426110B2 JP 4426110 B2 JP4426110 B2 JP 4426110B2 JP 2000578660 A JP2000578660 A JP 2000578660A JP 2000578660 A JP2000578660 A JP 2000578660A JP 4426110 B2 JP4426110 B2 JP 4426110B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- immobilized antibody
- antibody
- autoantibodies
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000003556 assay Methods 0.000 title description 13
- 239000000427 antigen Substances 0.000 claims abstract description 167
- 102000036639 antigens Human genes 0.000 claims abstract description 167
- 108091007433 antigens Proteins 0.000 claims abstract description 167
- 230000027455 binding Effects 0.000 claims abstract description 111
- 238000000034 method Methods 0.000 claims abstract description 96
- 210000001124 body fluid Anatomy 0.000 claims abstract description 76
- 239000000203 mixture Substances 0.000 claims abstract description 76
- 238000012216 screening Methods 0.000 claims abstract description 76
- 239000000758 substrate Substances 0.000 claims abstract description 76
- 239000010839 body fluid Substances 0.000 claims abstract description 63
- 238000002372 labelling Methods 0.000 claims abstract description 25
- 238000012544 monitoring process Methods 0.000 claims abstract description 15
- 108010036012 Iodide peroxidase Proteins 0.000 claims description 80
- 102000014267 Thyroid peroxidases Human genes 0.000 claims description 80
- 210000001685 thyroid gland Anatomy 0.000 claims description 34
- 210000002381 plasma Anatomy 0.000 claims description 33
- 102000011923 Thyrotropin Human genes 0.000 claims description 24
- 108010061174 Thyrotropin Proteins 0.000 claims description 24
- 239000013641 positive control Substances 0.000 claims description 18
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 17
- 239000000020 Nitrocellulose Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 16
- 229920001220 nitrocellulos Polymers 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000003911 Thyrotropin Receptors Human genes 0.000 claims description 15
- 108090000253 Thyrotropin Receptors Proteins 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 102000009843 Thyroglobulin Human genes 0.000 claims description 11
- 229960002175 thyroglobulin Drugs 0.000 claims description 11
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 9
- 108010034949 Thyroglobulin Proteins 0.000 claims description 9
- 229940034208 thyroxine Drugs 0.000 claims description 9
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 9
- 229940035722 triiodothyronine Drugs 0.000 claims description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims 4
- 230000009137 competitive binding Effects 0.000 claims 2
- 108010008775 thyroglobulin receptor Proteins 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 64
- 239000010931 gold Substances 0.000 description 41
- 229910052737 gold Inorganic materials 0.000 description 41
- 229910001112 rose gold Inorganic materials 0.000 description 17
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000005495 thyroid hormone Substances 0.000 description 9
- 229940036555 thyroid hormone Drugs 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 5
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 5
- 208000015943 Coeliac disease Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000006016 thyroid dysfunction Effects 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 208000024799 Thyroid disease Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000021510 thyroid gland disease Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000006449 Class 8 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 description 1
- 108010044226 Class 8 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000007884 postpartum thyroiditis Diseases 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/971—Capture of complex after antigen-antibody reaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/973—Simultaneous determination of more than one analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/805—Optical property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9823397.6 | 1998-10-27 | ||
| GBGB9823397.6A GB9823397D0 (en) | 1998-10-27 | 1998-10-27 | Assays for thyroid autoantibodies |
| PCT/GB1999/003548 WO2000025137A1 (en) | 1998-10-27 | 1999-10-27 | Assays for autoantibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002528722A JP2002528722A (ja) | 2002-09-03 |
| JP2002528722A5 JP2002528722A5 (https=) | 2006-09-14 |
| JP4426110B2 true JP4426110B2 (ja) | 2010-03-03 |
Family
ID=10841298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000578660A Expired - Lifetime JP4426110B2 (ja) | 1998-10-27 | 1999-10-27 | 自己抗体のためのアッセイ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7001775B1 (https=) |
| EP (1) | EP1071956B1 (https=) |
| JP (1) | JP4426110B2 (https=) |
| AT (1) | ATE323286T1 (https=) |
| DE (1) | DE69930843T2 (https=) |
| GB (1) | GB9823397D0 (https=) |
| WO (1) | WO2000025137A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1456234B1 (en) | 2001-08-23 | 2014-04-09 | Rsr Limited | Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| JP5662684B2 (ja) * | 2007-02-16 | 2015-02-04 | ジェンザイム コーポレーション | 甲状腺障害リスクの同定方法 |
| US20090286329A1 (en) * | 2008-05-19 | 2009-11-19 | Abbott Laboratoires | Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides |
| US20090286256A1 (en) * | 2008-05-19 | 2009-11-19 | Abbott Laboratories | Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides |
| WO2011085057A2 (en) * | 2010-01-06 | 2011-07-14 | The Regents Of The University Of Colorado, A Body Corporate | Methods for detecting insulin autoantibody |
| US12436148B2 (en) * | 2018-07-02 | 2025-10-07 | Siemens Healthcare Diagnostics Inc. | Direct immunoassay measurement of autoantibodies |
| US12163956B2 (en) * | 2019-02-21 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples |
| WO2020210446A1 (en) * | 2019-04-12 | 2020-10-15 | Dyax Corp. | Lateral flow immunoassay for measuring functional c1-esterase inhibitor (c1-inh) in plasma samples |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622871A (en) * | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
| US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| NL7501215A (nl) * | 1975-02-01 | 1976-08-03 | Akzo Nv | Methode voor het aantonen en bepalen van een antigeen of antilichaam. |
| US4094647A (en) | 1976-07-02 | 1978-06-13 | Thyroid Diagnostics, Inc. | Test device |
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| US4486530A (en) * | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4444879A (en) * | 1981-01-29 | 1984-04-24 | Science Research Center, Inc. | Immunoassay with article having support film and immunological counterpart of analyte |
| DE3484505D1 (de) * | 1983-12-19 | 1991-05-29 | Daiichi Pure Chemicals Co Ltd | Immuntest. |
| US4999285A (en) | 1984-11-15 | 1991-03-12 | Syntex (U.S.A.) Inc. | Chromatographic cassette |
| DE3445816C1 (de) | 1984-12-15 | 1986-06-12 | Behringwerke Ag, 3550 Marburg | Flaechenfoermiges diagnostisches Mittel |
| GB8526741D0 (en) | 1985-10-30 | 1985-12-04 | Boots Celltech Diagnostics | Binding assay device |
| US5120643A (en) * | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| US5206177A (en) * | 1988-01-21 | 1993-04-27 | Boehringer Mannheim Corporation | Apparatus for determining an analyte and method therefor |
| US5077198A (en) * | 1988-04-14 | 1991-12-31 | Eastman Kodak Company | Diagnostic kit and method for rapid detection of antibodies |
| WO1991003483A1 (en) * | 1989-09-08 | 1991-03-21 | New England Medical Center Hospitals, Inc. | Tsh receptor |
| CA2110920A1 (en) * | 1991-06-13 | 1992-12-23 | Sinfu Tzeng | Assay for the detection of specific ligands |
| DE4120412C1 (https=) * | 1991-06-20 | 1993-01-07 | Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De | |
| US5229073A (en) * | 1992-02-27 | 1993-07-20 | Abbott Laboratories | One-step competitive immunoassay for the semiquantitative determination of plasma lipoprotein(a) |
| WO1993023073A1 (en) * | 1992-05-19 | 1993-11-25 | The Regents Of The University Of Michigan | Thyroid peroxidase epitopic regions |
| WO1994012878A1 (en) * | 1992-11-27 | 1994-06-09 | Gec-Marconi Limited | Separation method |
| DE4328070C1 (de) | 1993-08-20 | 1994-11-24 | Henning Berlin Gmbh | Verfahren zur Bestimmung eines Analyten in einem Volumen einer flüssigen Probe sowie seine Anwendung zur Bestimmung von anti-TSH-Rezeptor-Autoantikörpern in einem Patientenserum |
| EP0719858A3 (en) | 1994-12-27 | 1997-12-29 | Tosoh Corporation | Myeloma cell line expressing recombinant human thyroid stimulating hormone receptor |
| WO1996027129A1 (en) | 1995-02-28 | 1996-09-06 | Ehrenkranz Joel R L | Rapid, self-performing tsh immunoassay |
-
1998
- 1998-10-27 GB GBGB9823397.6A patent/GB9823397D0/en not_active Ceased
-
1999
- 1999-10-27 US US09/582,524 patent/US7001775B1/en not_active Expired - Lifetime
- 1999-10-27 WO PCT/GB1999/003548 patent/WO2000025137A1/en not_active Ceased
- 1999-10-27 JP JP2000578660A patent/JP4426110B2/ja not_active Expired - Lifetime
- 1999-10-27 DE DE69930843T patent/DE69930843T2/de not_active Expired - Lifetime
- 1999-10-27 EP EP99951000A patent/EP1071956B1/en not_active Expired - Lifetime
- 1999-10-27 AT AT99951000T patent/ATE323286T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1071956A1 (en) | 2001-01-31 |
| GB9823397D0 (en) | 1998-12-23 |
| ATE323286T1 (de) | 2006-04-15 |
| JP2002528722A (ja) | 2002-09-03 |
| DE69930843T2 (de) | 2006-11-30 |
| US7001775B1 (en) | 2006-02-21 |
| WO2000025137A1 (en) | 2000-05-04 |
| DE69930843D1 (de) | 2006-05-24 |
| EP1071956B1 (en) | 2006-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4744147B2 (ja) | アフィニティー精製抗体を用いた甲状腺刺激ホルモン受容体自己抗体の同定 | |
| RU2058032C1 (ru) | Способ определения веществ, имеющих по меньшей мере одну область антигенной детерминанты | |
| US9435797B2 (en) | Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin | |
| EP0569800A1 (en) | Diagnosis of IDDM with a panel of immunoreagents | |
| US9199234B2 (en) | TSH antibodies for point-of-care immunoassay formats | |
| US9201078B2 (en) | TSH immunoassays and processes for performing TSH immunoassays in the presence of endogenous contaminants in restricted wash formats | |
| WO2008012650A2 (en) | An immunochromatography device for the diagnosis of diseases in a sample | |
| JP3499570B2 (ja) | Tshレセプター自己抗体を検出するためのレセプター結合アッセイ | |
| JP4426110B2 (ja) | 自己抗体のためのアッセイ | |
| US8617826B2 (en) | TSH immunoassays employing scavenging reagents for cross-reacting endocrine glycoprotein hormone analogues | |
| WO1996031778A1 (en) | Rapid assays for the detection of glutathione s-transferases | |
| CN114573692A (zh) | 用于检测嗜铬粒蛋白a的免疫测定与抗体 | |
| DE19806185C2 (de) | Immunoassay und Testkit zur Bestimmung von fucosyliertem Protein in einer biologischen Probe | |
| US20020106696A1 (en) | Test device for detecting semen and method of use | |
| JP2009085685A (ja) | インスリン受容体αサブユニットの測定試薬 | |
| EP3701264A1 (en) | Method and means for diagnosing autoimmune hepatitis using autoantibody markers | |
| IE903439A1 (en) | Agglutination assay | |
| Fletcher Jr | Update on pregnancy testing | |
| JP7106810B2 (ja) | 新規肺がんマーカー | |
| Rosenbaum et al. | The clinical use of thyroid autoantibodies | |
| CN116298319B (zh) | 一种用于联合检测人Tg和Cyfra21-1的试纸条 | |
| JPH026757A (ja) | 糖尿病用アッセイ方法、それに用いるキットおよび単クローン性抗体、および検出方法 | |
| JPS6353511B2 (https=) | ||
| Schott et al. | 11 Autoimmune thyroid diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060719 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060719 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090522 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091201 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091210 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4426110 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131218 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |